Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072568 | 0.79 | KDM4E (0.36) | — | |
| SCHEMBL23418702 | 0.78 | CYP1A2 (0.42) | — | |
| SCHEMBL10819640 | 0.78 | — | — | |
| SCHEMBL15784681 | 0.77 | — | — | |
| SCHEMBL10734663 | 0.76 | — | — | |
| SCHEMBL3074990 | 0.75 | HDAC3 (0.42) | ALDH1A1 | |
| SCHEMBL3068330 | 0.75 | HDAC3 (0.36) | ALDH1A1 | |
| SCHEMBL3071534 | 0.73 | HDAC3 (0.46) | ALDH1A1 | |
| SCHEMBL3062386 | 0.73 | HDAC3 (0.46) | ALDH1A1 | |
| SCHEMBL4090753 | 0.73 | CTSD (0.54) | SIGMAR1CACNA1HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | SIGMAR1 2927/4885CACNA1H 3128/4885ALDH1A1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.